Bryce Point Capital, LLC Madrigal Pharmaceuticals, Inc. Transaction History
Bryce Point Capital, LLC
- $345 Billion
- Q4 2024
A detailed history of Bryce Point Capital, LLC transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Bryce Point Capital, LLC holds 1,903 shares of MDGL stock, worth $647,343. This represents 0.17% of its overall portfolio holdings.
Number of Shares
1,903Holding current value
$647,343% of portfolio
0.17%Shares
1 transactions
Others Institutions Holding MDGL
# of Institutions
308Shares Held
22.4MCall Options Held
639KPut Options Held
641K-
Janus Henderson Group PLC London, X02.48MShares$843 Million0.28% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.04MShares$695 Million29.57% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.03MShares$690 Million6.48% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$678 Million6.74% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$672 Million4.49% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $5.82B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...